Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
11.48 (USD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 1.884 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.094 | 0.088 | 0.088 | 0.09 | 0.425 | 0.427 | 0.423 | 0.418 | 0.41 | 0.407 | 1.573 | 0.05 | 0.031 | 0.009 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0.094 | -0.088 | 1.796 | -0.09 | -0.425 | -0.427 | -0.423 | -0.418 | -0.41 | -0.407 | -1.573 | -0.05 | -0.031 | -0.009 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.953 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 33.226 | 29.109 | 29.883 | 25.872 | 19.453 | 17.989 | 22.826 | 21.584 | 17.627 | 27.054 | 16.009 | 15.975 | 12.523 | 11.91 | 10.692 | 6.289 | 4.673 | 1.947 | 0.795 | 0.91 |
| General & Administrative Expenses
| 4.395 | 4.421 | 4.456 | 4.544 | 3.889 | 3.612 | 6.776 | 5.635 | 5.595 | 6.239 | 7.245 | 5.782 | 5.239 | 4.612 | 4.758 | 3.842 | 3.195 | 0.539 | 0.248 | 0.107 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | -0.088 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4.395 | 4.421 | 4.456 | 4.456 | 3.889 | 3.612 | 6.776 | 5.635 | 5.595 | 6.239 | 7.245 | 5.782 | 5.239 | 4.612 | 4.758 | 3.842 | 3.195 | 0.539 | 0.248 | 0.107 |
| Other Expenses
| 0 | 0 | 0.017 | 0.093 | -0.079 | -0.044 | 0.011 | 0.067 | -0.12 | 0.02 | 0.006 | 0.01 | -0.056 | -0.001 | 0 | 0 | 0.001 | 0 | 0 | 0 |
| Operating Expenses
| 37.621 | 33.53 | 34.339 | 30.328 | 23.342 | 21.601 | 29.602 | 27.219 | 23.222 | 33.293 | 23.254 | 21.757 | 17.762 | 16.522 | 15.45 | 10.131 | 7.868 | 2.486 | 1.043 | 1.017 |
| Operating Income
| -37.621 | -33.53 | -34.339 | -30.416 | -23.342 | -21.601 | -29.602 | -27.219 | -23.222 | -33.293 | -23.254 | -21.757 | -17.762 | -16.522 | -15.45 | -10.131 | -7.868 | -2.486 | -1.043 | -1.017 |
| Operating Income Ratio
| 0 | 0 | 0 | -16.144 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.066 | 3.148 | 3.369 | 3.644 | 1.84 | 1.506 | 1.316 | 1.04 | 0.502 | 0.435 | 0.224 | 0.119 | 0.049 | 0.116 | 0.111 | 0 | 0.024 | 0.033 | -0.65 | 0 |
| Income Before Tax
| -34.555 | -30.382 | -30.97 | -26.772 | -21.502 | -20.095 | -28.286 | -26.179 | -22.72 | -32.858 | -23.03 | -21.638 | -17.713 | -16.406 | -15.339 | -10.131 | -7.844 | -2.453 | -1.693 | -1.017 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -14.21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -3.352 | 4.785 | -1.919 | -1.55 | -1.316 | -1.04 | -0.502 | -0.415 | -0.224 | -0.063 | -0.056 | -0.001 | 0.111 | 22.117 | 0.001 | 0.033 | 0.003 | 0 |
| Net Income
| -34.555 | -30.382 | -30.97 | -26.772 | -21.502 | -20.095 | -26.97 | -25.139 | -22.218 | -32.858 | -22.806 | -21.638 | -17.713 | -16.406 | -15.339 | -10.131 | -7.844 | -2.453 | -1.693 | -1.017 |
| Net Income Ratio
| 0 | 0 | 0 | -14.21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.6 | -0.54 | -0.56 | -0.49 | -0.48 | -0.49 | -0.67 | -0.63 | -0.55 | -0.82 | -0.57 | -0.54 | -0.45 | -0.42 | -0.39 | -0.5 | -0.21 | -0.17 | -0.12 | -0.072 |
| EPS Diluted
| -0.6 | -0.54 | -0.56 | -0.49 | -0.48 | -0.49 | -0.67 | -0.63 | -0.55 | -0.82 | -0.57 | -0.54 | -0.45 | -0.42 | -0.39 | -0.5 | -0.21 | -0.17 | -0.12 | -0.072 |
| EBITDA
| -37.621 | -33.436 | -34.251 | -30.328 | -23.252 | -21.502 | -29.602 | -27.122 | -23.131 | -33.208 | -23.17 | -21.565 | -17.712 | -16.491 | -15.441 | -10.127 | -7.842 | -2.451 | -1.037 | -1.014 |
| EBITDA Ratio
| 0 | 0 | 0 | -16.098 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |